^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Published date:
04/22/2021
Excerpt:
...patients treated with HMA+VEN–based regimens at The University of Texas MD Anderson Cancer Center...RAS mutations were enriched in patients with U2AF1 mutations and associated with inferior outcomes (median OS, 8 months)...active signaling mutations...K/NRAS)...RAS mutations were enriched in patients with U2AF1 mutations and associated with numerically lower CRc (and MRD− CR) rates.
Secondary therapy:
Hypomethylating agent
DOI:
https://doi.org/10.1182/bloodadvances.2020004173